Black Creek Investment Management Inc. Sells 865,557 Shares of Elanco Animal Health Incorporated (NYSE:ELAN)

Black Creek Investment Management Inc. cut its holdings in Elanco Animal Health Incorporated (NYSE:ELAN - Free Report) by 4.1% in the 4th quarter, according to its most recent 13F filing with the SEC. The firm owned 20,434,653 shares of the company's stock after selling 865,557 shares during the quarter. Elanco Animal Health comprises 11.7% of Black Creek Investment Management Inc.'s holdings, making the stock its 2nd biggest position. Black Creek Investment Management Inc. owned approximately 4.13% of Elanco Animal Health worth $247,464,000 as of its most recent SEC filing.

Other large investors have also bought and sold shares of the company. Wilmington Savings Fund Society FSB bought a new position in shares of Elanco Animal Health during the 3rd quarter worth approximately $35,000. Jones Financial Companies Lllp grew its position in Elanco Animal Health by 95.6% in the fourth quarter. Jones Financial Companies Lllp now owns 4,212 shares of the company's stock valued at $51,000 after purchasing an additional 2,059 shares in the last quarter. SRS Capital Advisors Inc. increased its stake in Elanco Animal Health by 221.2% in the 4th quarter. SRS Capital Advisors Inc. now owns 4,953 shares of the company's stock valued at $60,000 after buying an additional 3,411 shares during the last quarter. MRP Capital Investments LLC bought a new stake in Elanco Animal Health during the 4th quarter worth about $61,000. Finally, Blue Trust Inc. lifted its position in Elanco Animal Health by 47.7% during the 4th quarter. Blue Trust Inc. now owns 5,862 shares of the company's stock worth $71,000 after buying an additional 1,894 shares in the last quarter. 97.48% of the stock is owned by institutional investors.

Elanco Animal Health Price Performance

Elanco Animal Health stock traded up $0.34 during mid-day trading on Friday, reaching $8.44. 5,406,589 shares of the company were exchanged, compared to its average volume of 4,914,510. The company has a fifty day simple moving average of $10.32 and a 200-day simple moving average of $11.89. The firm has a market cap of $4.19 billion, a PE ratio of 21.11, a PEG ratio of 2.50 and a beta of 1.44. The company has a debt-to-equity ratio of 0.66, a current ratio of 2.55 and a quick ratio of 1.31. Elanco Animal Health Incorporated has a 12 month low of $8.02 and a 12 month high of $18.80.

Elanco Animal Health (NYSE:ELAN - Get Free Report) last issued its earnings results on Tuesday, February 25th. The company reported $0.14 EPS for the quarter, missing the consensus estimate of $0.15 by ($0.01). The business had revenue of $1.02 billion for the quarter, compared to analyst estimates of $1.01 billion. Elanco Animal Health had a return on equity of 6.78% and a net margin of 4.60%. The firm's revenue was down 1.4% compared to the same quarter last year. During the same period in the previous year, the firm posted $0.08 EPS. As a group, equities research analysts expect that Elanco Animal Health Incorporated will post 0.91 earnings per share for the current fiscal year.

Insider Activity at Elanco Animal Health

In other Elanco Animal Health news, Director Lawrence Erik Kurzius acquired 10,000 shares of the company's stock in a transaction that occurred on Tuesday, March 11th. The stock was acquired at an average price of $10.20 per share, for a total transaction of $102,000.00. Following the acquisition, the director now directly owns 111,459 shares in the company, valued at $1,136,881.80. This represents a 9.86 % increase in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available at the SEC website. 0.57% of the stock is currently owned by company insiders.

Wall Street Analyst Weigh In

ELAN has been the topic of several analyst reports. Morgan Stanley dropped their target price on Elanco Animal Health from $14.00 to $13.00 and set an "equal weight" rating on the stock in a report on Wednesday, February 26th. UBS Group cut their price objective on Elanco Animal Health from $18.00 to $17.00 and set a "buy" rating for the company in a report on Wednesday, February 26th. Stifel Nicolaus dropped their price target on shares of Elanco Animal Health from $15.00 to $13.00 and set a "buy" rating on the stock in a research report on Monday. Barclays decreased their price objective on shares of Elanco Animal Health from $20.00 to $19.00 and set an "overweight" rating for the company in a research report on Wednesday, February 26th. Finally, Piper Sandler dropped their target price on shares of Elanco Animal Health from $16.00 to $12.00 and set a "neutral" rating on the stock in a report on Thursday, March 6th. Four investment analysts have rated the stock with a hold rating and three have assigned a buy rating to the stock. Based on data from MarketBeat.com, Elanco Animal Health presently has a consensus rating of "Hold" and a consensus price target of $14.67.

Elanco Animal Health Profile

Elanco Animal Health Incorporated, an animal health company, innovates, develops, manufactures, and markets products for pets and farm animals. It offers pet health disease prevention products, such as parasiticide and vaccine products that protect pets from worms, fleas, and ticks under the Seresto, Advantage, Advantix, and Advocate brands; pet health therapeutics for pain, osteoarthritis, ear infections, cardiovascular, and dermatology indications in canines and felines under the Galliprant and Claro brands; vaccines, antibiotics, parasiticides, and other products for use in poultry and aquaculture production, as well as nutritional health products, including enzymes, probiotics, and prebiotics; and a range of vaccines, antibiotics, implants, parasiticides, and other products used in ruminant and swine production under the Rumensin and Baytril brands.